pI: 7.0232 |
Length (AA): 532 |
MW (Da): 60878 |
Paralog Number:
1
Signal peptide: Y | GPI Anchor: N | Predicted trans-membrane segments: 2
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 5 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
163 | 525 | 1om1 (A) | 33 | 326 | 15.00 | 0 | 0.7 | 0.6 | 0.29 |
172 | 461 | 1jpa (A) | 632 | 878 | 15.00 | 0.0000000000016 | 0.91 | 0.35 | 0.69 |
258 | 463 | 1u46 (A) | 177 | 377 | 12.00 | 0.00000008 | 0.4 | 0.46 | -0.21 |
99 | 484 | 4ped (A) | 259 | 644 | 17.00 | 0.000000000006 | 1 | 1.01796 | -0.83 |
162 | 359 | 3is5 (A) | 132 | 286 | 28.00 | 0.14 | 0.46 | 0.31698 | 1.04 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | amastigotes, metacyclic. | Fernandes MC |
Fernandes MC | Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures. |
Ortholog group members (OG5_128411)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT1G61640 | ABC1 domain-containing kinase |
Arabidopsis thaliana | AT1G11390 | protein kinase-like protein ABC1K10 |
Brugia malayi | Bm1_21555 | hypothetical protein |
Candida albicans | CaO19.4575 | similar to S. cerevisiae YPL109C |
Candida albicans | CaO19.12044 | similar to S. cerevisiae YPL109C |
Caenorhabditis elegans | CELE_Y32H12A.7 | Protein Y32H12A.7 |
Dictyostelium discoideum | DDB_G0267774 | ABC1 family protein kinase |
Escherichia coli | b3835 | regulator of octaprenylphenol hydroxylation, ubiquinone synthesis |
Homo sapiens | ENSG00000133597 | aarF domain containing kinase 2 |
Leishmania braziliensis | LbrM.10.0740 | hypothetical protein, conserved |
Leishmania braziliensis | LbrM.35.6400 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_366350.1 | ABC1 family, putative |
Leishmania donovani | LdBPK_100650.1 | ABC1 family, putative |
Leishmania infantum | LinJ.36.6350 | hypothetical protein, conserved |
Leishmania infantum | LinJ.10.0650 | hypothetical protein, conserved |
Leishmania major | LmjF.10.0600 | hypothetical protein, conserved |
Leishmania major | LmjF.36.6090 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.10.0600 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.36.6090 | hypothetical protein, conserved |
Loa Loa (eye worm) | LOAG_00021 | atypical/ABC1/ABC1-C protein kinase |
Mus musculus | ENSMUSG00000046947 | aarF domain containing kinase 2 |
Oryza sativa | 4343579 | Os07g0558000 |
Oryza sativa | 4337281 | Os04g0660200 |
Onchocerca volvulus | OVOC7827 |
|
Saccharomyces cerevisiae | YPL109C | hypothetical protein |
Schmidtea mediterranea | mk4.059115.00 | |
Trypanosoma brucei gambiense | Tbg972.8.3740 | hypothetical protein, conserved |
Trypanosoma brucei gambiense | Tbg972.10.10590 | hypothetical protein, conserved |
Trypanosoma brucei | Tb927.10.8730 | ABC1 family, putative |
Trypanosoma brucei | Tb927.8.4000 | ABC1 family, putative |
Trypanosoma congolense | TcIL3000_10_7520 | hypothetical protein, conserved |
Trypanosoma congolense | TcIL3000_0_22430 | hypothetical protein, conserved |
Trypanosoma cruzi | TcCLB.507623.90 | ABC1 family, putative |
Trypanosoma cruzi | TcCLB.505941.30 | ABC1 family, putative |
Trypanosoma cruzi | TcCLB.509789.10 | ABC1 family, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.10.8730 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.10.8730 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.10.8730 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb927.10.8730 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
Tb927.8.4000 | Trypanosoma brucei | significant gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.8.4000 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.8.4000 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.8.4000 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
b3835 | Escherichia coli | essential | goodall |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.1